20041209
 Pfizer Inc.   The Wall Street Journal,  Dec 10, 2004  The Food and Drug Administration approved a new label for Pfizer Inc.'s arthritis-pain drug Bextra that adds a warning about a risk of heart and blood-clotting problems for patients who recently had coronary artery bypass graft surgery.   
